FDA warns testing companies: Don’t tell patients how their DNA influences response to specific drugs
FDA imposes more scrutiny on efficacy and safety claims resulting from pharmacogenetics testing concerned about inappropriate use in patient care. More
Read MoreComplex Innovative Trial Designs Pilot Program
FDA announces a set of presentations and a pilot program to advance Complex Innovative Clinical Trial Designs (CIDs) as a part of PDUFA VI (Aug 2017). The initiative is aimed…
Read More